Where does X4 Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), X4 Pharmaceuticals, Inc. ranks #18,301 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does X4 Pharmaceuticals, Inc. hold?

X4 Pharmaceuticals, Inc. holds 16 US utility patents granted between 2020 and 2025, spanning 5 technology areas.

What is X4 Pharmaceuticals, Inc.'s Innovation Score?

X4 Pharmaceuticals, Inc. has an Innovation Score of 37.9 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does X4 Pharmaceuticals, Inc. focus on?

X4 Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 16 patents, ranking #1,230 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is X4 Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for X4 Pharmaceuticals, Inc..

What does claim depth mean for X4 Pharmaceuticals, Inc.'s patents?

X4 Pharmaceuticals, Inc.'s patents average 18.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the X4 Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

X4 Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 16 granted patents across 5 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, X4 ranks #18,301 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 5 technology areas.

#18,301
of 49,997 US assignees by volume: Top 42%
by Innovation Score (37.9/100): 18.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R18301 · US Corporation #18,301 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 16 grants
MID-PACK #18,301/49,997
PHOTO-FINISH World Wide Daily…
CPC-NARROW A61P · 5 areas
INNOV-THIN 37.9/100
CLAIMS-RICH 18.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: World Wide Daily Holdings Company Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How X4’s 37.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (26%) Velocity 8.9 pts (23%) Breadth 7.9 pts (21%) Claim depth 11.3 pts (30%)

Qualcomm Incorporated · highest

85
X4 Pharmaceuticals · this assignee

38
3D Lighting… · lowest

7

What this shows X4's Innovation Score is 37.9/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for X4?

Each dot is one of X4’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). X4’s own 18.8 claims/patent is ABOVE the 10.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

X4 vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where X4's grants concentrate

X4 Pharmaceuticals, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (5 grants) versus a trough of 1 in 2024. By volume, X4 sits between World Wide Daily Holdings Company Limited and Xtreme Orthopedics LLC.

X4's three-year grant acceleration

X4 Pharmaceuticals, Inc. shows 8 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

World Wide Daily…

16
Worldwide Pro

16
Worthen Industries

16
X-energy

16
Xebec Technology

16
Xenotherapeutics

16
Xi'an Creation Ke…

16
Xtreme Orthopedics

16
X4 Pharmaceuticals ◀

16

What this shows X4 holds 16 patents at rank #18,297, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near X4

By rank, the assignees closest to #18,297 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in X4's primary technology class.

X4's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

X4 Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	3	18.8%
2021	3	18.8%
2022	5	31.3%
2023	2	12.5%
2024	1	6.3%
2025partial year	2	12.5%

Which technologies does X4 Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 16

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

C07D - Heterocyclic Compounds 7

Y02A - Technologies FOR Adaptation TO Climate Change 2

C07K - Peptides 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

X4 Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

X4 Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #18,301 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare X4 Pharmaceuticals, Inc. against World Wide Daily Holdings Company Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.